The Department of Veterans Affairs National Acquisition Center awarded a single-award Indefinite Delivery Contract (IDC) to Xlcare Pharmaceuticals Inc., a minority-owned, small disadvantaged business and certified economically disadvantaged woman-owned small business, to supply pantoprazole tablets. The contract has a total potential value of $28,973,375.80 and covers an initial one-year base period from June 26, 2022 to June 25, 2023, with four one-year option periods. The pantoprazole tablets will be distributed through the VA's Pharmaceutical Prime Vendor program to support the VA, Bureau of Prisons, and Indian Health Service. The original pre-solicitation notice estimated annual requirements of 160,011 bottles of 20mg pantoprazole, 687,323 bottles of 40mg pantoprazole, and 47,921 bottles of 40mg pantoprazole 1000ct bottles. Xlcare Pharmaceuticals has previously held other IDC awards with the VA to supply various pharmaceutical products including losartan potassium, lamivudine/zidovudine, lacosamide, and dutasteride.
Generated 5/11/24, 9:06 AM